MicroRNA from stem cells could be used to treat babies while still in the womb
29 Apr 2021, 3:11 p.m.
Using tiny liquid ‘bubbles’ of microRNAs from stem cells, a team of researchers from Great Ormond Street Hospital (GOSH) and The Hospital for Sick Children (SickKids, in Toronto has regenerated under-developed lungs in rats while still in the womb.
As babies develop in the womb, the growth of their lungs is a critical part of development, and any disruptions can lead to under-developed lungs, leading to disability or even stillbirth. Known as ‘pulmonary hypoplasia’, this condition usually occurs alongside other medical conditions or due to other malformations, like when the diaphragm fails to properly close during development. Infants born with the severest cases only have a survival rate of 60% and those who do survive face a lifetime of complications. Treatment options can involve surgery even before the baby is born but irreparable damage is often done to the lungs.
Now, scientists and doctors from two of the world’s leading children’s hospitals have come together to take advantage of the regenerative properties of stem cells isolated from amniotic fluid. These cells produce tiny liquid ‘bubbles’, called vesicles, containing microRNAs that boost the genes that support the developing lung. The team found that using microRNAs isolated from a donor’s amniotic fluid stimulated lung growth, proper lung structure, and the creation of lung cells in the laboratory and in animal models of pulmonary hypoplasia.
Professor Paolo De Coppi (pictured), Consultant Paediatric Surgeon at GOSH and Head of Stem Cells and Regenerative Medicine at GOS UCL ICH said: "Stem cells are well-known to have anti-inflammatory effects, but this is the first time we have shown that it is the vesicles – containing microRNA – that are capable of this regenerative effect. By using a donor for the stem cells, we are able to create something you can use ‘off-the-shelf’ and by using the vesicles and not the whole stem cells, we remove the risk of potentially cancerous side effects.”
Professor Augusto Zani, Neonatal and Paediatric Surgeon, Division of General and Thoracic Surgery, and Scientist in the Developmental and Stem Cell Biology program at SickKids said: “We have built on the stem cell research developed by collaborators at GOSH and applied it to a whole new disease – it’s very exciting. Our next steps will be to show that this works in humans but we are hopeful from preliminary data that this will be successful. The long-term vision is to get this treatment into a clinical trial for babies born with severe malformations of the diaphragm.”
All research at Great Ormond Street Hospital is supported by the NIHR GOSH BRC.
Common inflammatory bowel disease treatment is linked to reduced COVID-19 antibody response
New evidence indicates the commonly-prescribed inflammatory bowel disease (IBD) drug infliximab blunts the immune system to COVID-19 infection, potentially increasing the risk of reinfection.
GOSH and UCL researchers receive funding to improve outcomes for children and young people with cancer
Researchers at University College London and Great Ormond Street Hospital receive £1.7m of grants in new Cancer Research UK-Children with Cancer UK Innovation Awards.
MRI scans more precisely define and detect some abnormalities in unborn babies
MRI scanning can more precisely define and detect head, neck, thoracic, abdominal and spinal malformations in unborn babies, finds a large multidisciplinary study led by Evelina London Children’s Hospital, Great Ormond Street Hospital and UCL.
Cellular benefits of gene therapy seen decades after treatment
An international collaboration has shown the beneficial effects of gene therapy can be seen decades after the transplanted blood stem cells have been cleared by the body.